Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy

Core Insights - Teleflex Incorporated has launched Barrigel™ rectal spacer in Japan, following regulatory approval and insurance coverage acceptance, marking a significant step in its global expansion strategy [3][5][11] - Barrigel™ is the first and only sculptable non-animal stabilized hyaluronic acid (NASHA) rectal spacer, designed to reduce radiation exposure to the rectum during prostate cancer treatment [4][9] - In 2022, prostate cancer was the most common cancer among men in Japan, with 104,318 new cases, representing 18% of all cancer diagnoses nationwide [5] Product Details - Barrigel™ rectal spacer has demonstrated a 98% success rate in achieving at least a 25% reduction in radiation to the rectum in a U.S. clinical study, with an average reduction of 85% in rectal V54 Gy radiation [6] - The product is indicated for prostate cancer patients with T1-T3b disease and is cleared for use in the U.S., Australia, Europe, and Japan [11][12] - Barrigel™ is made from biodegradable NASHA, which is biocompatible and fully absorbable, ensuring safety and efficacy in various medical applications [10][12] Market Impact - The launch in Japan is expected to enhance access to Barrigel™ for men undergoing prostate cancer radiation therapy, minimizing rectal side effects [7] - Teleflex aims to establish Barrigel™ as the standard of care for prostate cancer radiation therapy, emphasizing its innovative technology and precision in placement [5][8] - Training for healthcare professionals in Japan has commenced, led by top radiation oncologists, to ensure effective implementation of the product [8]